The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms.

autophagy biomarker drug development uveal melanoma

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
19 Feb 2024
Historique:
received: 23 01 2024
revised: 15 02 2024
accepted: 17 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Autophagy is a form of programmed cell degradation that enables the maintenance of homeostasis in response to extracellular stress stimuli. Autophagy is primarily activated by starvation and mediates the degradation, removal, or recycling of cell cytoplasm, organelles, and intracellular components in eukaryotic cells. Autophagy is also involved in the pathogenesis of human diseases, including several cancers. Human uveal melanoma (UM) is the primary intraocular malignancy in adults and has an extremely poor prognosis; at present there are no effective therapies. Several studies have suggested that autophagy is important in UM. By understanding the mechanisms of activation of autophagy in UM it may be possible to develop biomarkers to provide more definitive disease prognoses and to identify potential drug targets for the development of new therapeutic strategies. This article reviews the current information regarding autophagy in UM that could facilitate biomarker and drug development.

Identifiants

pubmed: 38398064
pii: biomedicines12020462
doi: 10.3390/biomedicines12020462
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : NIEHS NIH HHS
ID : R35 ES030443
Pays : United States

Auteurs

Janney Z Wang (JZ)

Molecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Paus Paulus (P)

Molecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Yihe Niu (Y)

Molecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Ling Zhu (L)

Save Sight Institute, The University of Sydney, Sydney, NSW 2006, Australia.

Christophe Morisseau (C)

Department of Entomology and Nematology, UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.

Tristan Rawling (T)

School of Mathematical and Physical Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.

Michael Murray (M)

Molecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Bruce D Hammock (BD)

Department of Entomology and Nematology, UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.

Fanfan Zhou (F)

Molecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Classifications MeSH